ESR1 and uterine cancer: In addition, most (if not all) the other ligands are estrogenic in nature [53], and could thus act as positive factors for ER-dependent breast, ovary and uterine cancers, whereas PTER-ITC is anti-estrogenic at the dose used for this study.